Tampereen yliopistollinen sairaala
Welcome,         Profile    Billing    Logout  
 3 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tammela, Teuvo L
NCT03139734: Sacral Neuromodulation for Pelvic Pain Associated With Endometriosis

Recruiting
N/A
50
Europe
Sacral Neuromodulation, Sacral Nerve Stimulation, Sacral Nerve Modulation
Seinajoki Central Hospital, Helsinki University Central Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital, Jyväskylä Central Hospital
Endometriosis
05/22
05/22
SPCG-15, NCT02102477: Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer

Recruiting
N/A
1200
Europe
Prostatectomy/Surgery, Radiotherapy with adjuvant androgen deprivation therapy
Olof Akre
Prostatic Neoplasms
12/25
12/45
Petit, Benedicte
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
TREAT ctDNA, NCT05512364: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting
3
220
Europe
Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
07/28
05/30
Jalkanen, Ville
GODIF, NCT04180397: Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.

Recruiting
4
1000
Europe, RoW
Furosemide, Furix, Isotonic saline
Morten H. Bestle, University of Copenhagen, Copenhagen Trial Unit, Center for Clinical Intervention Research, Centre for Research in Intensive Care (CRIC)
Fluid Overload
12/26
03/28
Tinza-SLEDD, NCT03614741: Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients

Recruiting
4
60
Europe
Tinzaparin continuous infusion, Tinzaparin bolus
Tampere University Hospital
Acute Kidney Injury, Renal Replacement Therapy, Anticoagulants
12/25
12/25
FLUID-ICU, NCT06258616: Fluid Administration and Fluid Accumulation in the Intensive Care Unit

Recruiting
N/A
1000
Europe, RoW
Nordsjaellands Hospital, University of Copenhagen, Rigshospitalet, Denmark
Fluid Accumulation, Fluid Therapy, Fluid Overload
05/25
08/25
NCT05250453: Quality of the Cardio-pulmonary Resuscitation

Recruiting
N/A
400
Europe
Tampere University Hospital, National Istitute For Health and Welfare, Finland
Cardiopulmonary Resuscitation
03/23
07/23
Tanner, Minna
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT04796324 / 2020-004610-35: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Recruiting
2
60
Europe
Ixabepilone Injection
Allarity Therapeutics, Allarity Therapeutics
Metastatic Breast Cancer
10/24
11/25
FINPROVE, NCT05159245 / 2021-000689-14: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
2
250
Europe
Alectinib, Alecensa, Cobimetinib, Cotellic, Vismodegib, Erivedge, Trastuzumab+Pertuzumab, Phesgo, Entrectinib, Rozlytrek, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf, Regorafenib, Stivarga, Apalutamide, Erleada, Abemaciclib, Verzenio, Tepotinib, Tepmetko, Dabrafenib, Tafinlar, Trametinib, Mekinist, Dabrafenib+Trametinib, Tafinlanr+Mekinist, Pemigatinib, Pemazyre
Helsinki University Central Hospital, Helsinki University Hospital
Advanced Cancer, Solid Tumor, Haematological Malignancy
11/26
11/26
Debaere, Debbie
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Pollari, Marjukka
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Recruiting
2
208
Europe, RoW
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
81
Europe, RoW
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Nordic Lymphoma Group, AstraZeneca
MCL, Mantle Cell Lymphoma
01/27
01/27
2018-523-00US1, NCT03779113: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Active, not recruiting
1
140
Europe, US
HMPL-523
Hutchmed
Non Hodgkin Lymphoma
12/24
01/26
CAPCI, NCT06755619: CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)

Recruiting
N/A
60
Europe
Nordic Lymphoma Group
Primary Central Nervous System (CNS) Lymphoma
12/30
12/38
Rorive, Andrée
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32

Download Options